CMTM4 is a subunit of the IL-17 receptor and mediates autoimmune pathology

Nat Immunol. 2022 Nov;23(11):1644-1652. doi: 10.1038/s41590-022-01325-9. Epub 2022 Oct 21.


Interleukin-17A (IL-17A) is a key mediator of protective immunity to yeast and bacterial infections but also drives the pathogenesis of several autoimmune diseases, such as psoriasis or psoriatic arthritis. Here we show that the tetra-transmembrane protein CMTM4 is a subunit of the IL-17 receptor (IL-17R). CMTM4 constitutively associated with IL-17R subunit C to mediate its stability, glycosylation and plasma membrane localization. Both mouse and human cell lines deficient in CMTM4 were largely unresponsive to IL-17A, due to their inability to assemble the IL-17R signaling complex. Accordingly, CMTM4-deficient mice had a severe defect in the recruitment of immune cells following IL-17A administration and were largely resistant to experimental psoriasis, but not to experimental autoimmune encephalomyelitis. Collectively, our data identified CMTM4 as an essential component of IL-17R and a potential therapeutic target for treating IL-17-mediated autoimmune diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arthritis, Psoriatic*
  • Encephalomyelitis, Autoimmune, Experimental* / genetics
  • Humans
  • Interleukin-17 / metabolism
  • MARVEL Domain-Containing Proteins / genetics
  • Mice
  • Psoriasis*
  • Receptors, Interleukin-17 / genetics
  • Receptors, Interleukin-17 / metabolism


  • Receptors, Interleukin-17
  • Interleukin-17
  • CMTM4 protein, human
  • MARVEL Domain-Containing Proteins